Literature DB >> 20602605

Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2,3-dioxygenase and serotonin in immature dendritic cells: Implications for neuroAIDS.

Thangavel Samikkannu1, Kurapati V K Rao, Nimisha Gandhi, Shailendra K Saxena, Madhavan P N Nair.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) is commonly associated with immune dysfunctions and the suppression of antigen-presenting cells. This results in immune alterations, which could lead to impaired neuronal functions, such as neuroAIDS. The neurotoxic factor kynurenine (KYN), the rate-limiting enzyme indoleamine 2,3-dioxygenase (IDO), serotonin (5-HT), and serotonin transporter (5-HTT) may play a role in tryptophan deficiency and serotogenic dysfunction in neuroAIDS. HIV-1 transactivator regulatory protein (Tat) is known to play a major role in immune dysfunction. Previous studies suggest that HIV-1 B and C clades differentially manifest neuronal dysfunctions in the infected host. In the present study we examine the effect of HIV-1 B and C clade-derived Tat on IDO and 5-HTT gene and protein expressions by dendritic cells as studied by quantitative polymerase chain reaction (qPCR) and Western blot. In addition, the intracellular IDO expression, IDO enzyme activity, and the levels of 5-HT and KYN were also measured. Results indicate that HIV-1 clade B Tat up-regulates IDO and down-regulates 5-HTT gene and protein expressions. Further, HIV-1 clade B Tat caused a reduction of 5-HT with simultaneous increase in KYN levels as compared to HIV-1 clade C Tat. These studies suggest that HIV-1 clade B and C Tat proteins may play a differential role in the neuropathogenesis of HIV-associated dementia (HAD) or HIV-associated neurocognitive disorder (HAND).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20602605     DOI: 10.3109/13550284.2010.497809

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  50 in total

1.  HIV-1 nomenclature proposal.

Authors:  D L Robertson; J P Anderson; J A Bradac; J K Carr; B Foley; R K Funkhouser; F Gao; B H Hahn; M L Kalish; C Kuiken; G H Learn; T Leitner; F McCutchan; S Osmanov; M Peeters; D Pieniazek; M Salminen; P M Sharp; S Wolinsky; B Korber
Journal:  Science       Date:  2000-04-07       Impact factor: 47.728

2.  1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity.

Authors:  Sophie Agaugué; Laure Perrin-Cocon; Frédéric Coutant; Patrice André; Vincent Lotteau
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

3.  Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate.

Authors:  S R Thomas; H Salahifar; R Mashima; N H Hunt; D R Richardson; R Stocker
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

4.  Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000.

Authors:  Saladin Osmanov; Claire Pattou; Neff Walker; Bernhard Schwardländer; Jose Esparza
Journal:  J Acquir Immune Defic Syndr       Date:  2002-02-01       Impact factor: 3.731

5.  Drug abuse and neuropathogenesis of HIV infection: role of DC-SIGN and IDO.

Authors:  Madhavan P N Nair; Stanley A Schwartz; Supriya D Mahajan; Chubin Tsiao; Ram P Chawda; Robert Whitney; Bindukumar B Don Sykes; Ross Hewitt
Journal:  J Neuroimmunol       Date:  2004-12       Impact factor: 3.478

6.  Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Jeffrey R Lee; Kanchan G Jhaver; Theodore S Johnson; Derin B Keskin; Brendan Marshall; Phillip Chandler; Scott J Antonia; Russell Burgess; Craig L Slingluff; Andrew L Mellor
Journal:  Science       Date:  2002-09-13       Impact factor: 47.728

Review 7.  IDO expression by dendritic cells: tolerance and tryptophan catabolism.

Authors:  Andrew L Mellor; David H Munn
Journal:  Nat Rev Immunol       Date:  2004-10       Impact factor: 53.106

8.  Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection.

Authors:  Melody G Duvall; Karin Loré; Hetty Blaak; David A Ambrozak; William C Adams; Kathlyn Santos; Christof Geldmacher; John R Mascola; Andrew J McMichael; Assan Jaye; Hilton C Whittle; Sarah L Rowland-Jones; Richard A Koup
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

Review 9.  The interaction of immunodeficiency viruses with dendritic cells.

Authors:  R M Steinman; A Granelli-Piperno; M Pope; C Trumpfheller; R Ignatius; G Arrode; P Racz; K Tenner-Racz
Journal:  Curr Top Microbiol Immunol       Date:  2003       Impact factor: 4.291

10.  Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors.

Authors:  A Granelli-Piperno; B Moser; M Pope; D Chen; Y Wei; F Isdell; U O'Doherty; W Paxton; R Koup; S Mojsov; N Bhardwaj; I Clark-Lewis; M Baggiolini; R M Steinman
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307

View more
  15 in total

Review 1.  HIV-1 gp120 and drugs of abuse: interactions in the central nervous system.

Authors:  Peter S Silverstein; Ankit Shah; James Weemhoff; Santosh Kumar; D P Singh; Anil Kumar
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

2.  Human immunodeficiency virus type 1 clade B and C gp120 differentially induce neurotoxin arachidonic acid in human astrocytes: implications for neuroAIDS.

Authors:  Thangavel Samikkannu; Marisela Agudelo; Nimisha Gandhi; Pichili V B Reddy; Zainulabedin M Saiyed; Donald Nwankwo; Madhavan P N Nair
Journal:  J Neurovirol       Date:  2011-04-14       Impact factor: 2.643

3.  Latest trends in drugs of abuse - HIV infection and neuroAIDS.

Authors:  Sneham Tiwari; Madhavan Pn Nair; Shailendra K Saxena
Journal:  Future Virol       Date:  2013-02       Impact factor: 1.831

Review 4.  Homeostasis and function of regulatory T cells in HIV/SIV infection.

Authors:  Maria E Moreno-Fernandez; Pietro Presicce; Claire A Chougnet
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

5.  Immunoneuropathogenesis of HIV-1 clades B and C: role of redox expression and thiol modification.

Authors:  Thangavel Samikkannu; Kurapati V K Rao; Sudhessh Pilakka Kanthikeel; Venkata Subba Rao Atluri; Marisela Agudelo; Upal Roy; Madhavan P N Nair
Journal:  Free Radic Biol Med       Date:  2014-01-27       Impact factor: 7.376

6.  HIV-1 subtypes B and C Tat differentially impact synaptic plasticity expression and implicates HIV-associated neurocognitive disorders.

Authors:  Thangavel Samikkannu; Venkata S R Atluri; Adriana Y Arias; Kesava V K Rao; Carmen T Mulet; Rahul D Jayant; Madhavan P N Nair
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

7.  HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms.

Authors:  Rémi Planès; Lbachir BenMohamed; Kaoutar Leghmari; Pierre Delobel; Jacques Izopet; Elmostafa Bahraoui
Journal:  J Virol       Date:  2014-04-02       Impact factor: 5.103

8.  HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner.

Authors:  Xin Fu; Marcus A Lawson; Keith W Kelley; Robert Dantzer
Journal:  J Neuroinflammation       Date:  2011-08-02       Impact factor: 8.322

9.  HIV-1 Tat Protein Induces Production of Proinflammatory Cytokines by Human Dendritic Cells and Monocytes/Macrophages through Engagement of TLR4-MD2-CD14 Complex and Activation of NF-κB Pathway.

Authors:  Nawal Ben Haij; Rémi Planès; Kaoutar Leghmari; Manutea Serrero; Pierre Delobel; Jacques Izopet; Lbachir BenMohamed; Elmostafa Bahraoui
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

10.  HIV-1 Tat protein induces the production of IDO in human monocyte derived-dendritic cells through a direct mechanism: effect on T cells proliferation.

Authors:  Rémi Planès; Elmostafa Bahraoui
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.